Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-18

Study Completion Date

2018-10-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label study to compare systemic exposure to triamcinolone acetonide following a dose of extended-release FX006 or immediate-release TAcs (triamcinolone acetonide suspension) in patients with osteoarthritis of the shoulder (glenohumeral joint) or hip

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

NCT03378076

Bilateral Knee Osteoarthritis

COMPLETED PHASE2

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

NCT02637323

Osteoarthritis of the Knee

COMPLETED PHASE2

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

NCT02003365

Osteoarthritis of the Knee

COMPLETED PHASE2

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

NCT03793010

Osteoarthritis, Hip

TERMINATED PHASE3

Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip

NCT04065074

Osteoarthritis, Hip

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, open-label, single dose study that will be conducted in male and female patients ≥40 years of age with OA of either the shoulder or the hip.

Approximately 24 patients with OA of the shoulder and approximately 24 patients with OA of the hip will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either:

* 32 mg FX006 (approximately 12 patients per joint) or
* 40 mg TAcs (approximately 12 patients per joint)

Each patient will be screened to confirm the diagnosis of OA of either the shoulder or hip and eligibility based on the other inclusion/exclusion requirements and will be randomized to treatment on Day 1. Each patient will be evaluated for a total of 12 weeks following the IA injection. Following screening, sampling for pharmacokinetics (PK) and safety will be completed at 10 out-patient visits scheduled on Study Days 1 \[calendar day of injection\], 2, 3, 5, 8, 15, 22, 29, 57, and 85.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis of the Shoulder Osteoarthritis of the Hip

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FX006 32 mg

Single intra-articular (IA) injection of FX006 32 mg

Group Type EXPERIMENTAL

FX006 32 mg

Intervention Type DRUG

Extended-release 32 mg FX006 IA injection

TAcs 40 mg

Single intra-articular (IA) injection of TAcs 40 mg

Group Type ACTIVE_COMPARATOR

TAcs 40 mg

Intervention Type DRUG

Immediate-release 40mg TAcs IA injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FX006 32 mg

Extended-release 32 mg FX006 IA injection

Intervention Type DRUG

TAcs 40 mg

Immediate-release 40mg TAcs IA injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zilretta Kenalog®-40 Injection Triamcinolone Acetonide Crystalline Suspension (TAcs) TCA-IR 40

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written consent to participate in the study
* Male or female greater than or equal to 40 years of age
* Body mass index (BMI) less than or equal to 40 kg/m2
* Ambulatory and in good general health
* Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions
* Willing to abstain from use of protocol-restricted treatments from Screening through End-of-Study visit
* Symptoms consistent with OA of the index joint for ≥ 6 months prior to Screening (patient reported is acceptable)
* Pain in the index joint for greater than15 days over the last month (as reported by the patient)
* For Shoulder OA patients: Radiologic findings of OA of the index shoulder meeting the Samilson-Prieto (S-P) Classification Grades 2 or 3
* For Hip OA patients: ACR Criteria (clinical and radiological) for OA of the index hip

Exclusion Criteria

* Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
* History of infection in the index joint
* Clinical findings consistent with active infection or crystal disease in the index joint within 1 month of Screening
* History of fracture in the index limb within 12 months of Screening, or fracture with sequelae at any time
* Planned or anticipated surgery of the index joint during the study period
* Index joint instability or history of acute dislocation within 12 months of Screening
* If shoulder is the index joint, history of full or partial rotator cuff tear or significantly compromised rotator cuff function that, in the opinion for the Investigator, increases the difficulty or risk of IA injection
* Presence of surgical hardware or other foreign body in the index joint
* Surgery or arthroscopy of the index joint within 12 months of Screening
* IA treatment of any joint with any of the following agents within 6 months of Screening:
* Any corticosteroid preparation (investigational or marketed, including FX006), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed)
* IA treatment of the index joint with hyaluronic acid (investigational or marketed) within 6 months of Screening
* Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
* Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
* Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No